Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8690-002 in Moderately to Severely Active Ulcerative Colitis
2025-523479-49-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of aprepitant in autoimmune colitis (2 arms), sponsored by Merck & Co. Primary endpoint: Clinical remission per Modified Mayo Score at Week 12. Planned start Jun 2026; status: authorised.
02
Drugs
aprepitant
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-523479-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523479-49-00.